Events
Düsseldorf, July 17, 2025 – Priavoid expands its executive management by the appointments of Prof. Dr. Dieter Willbold as Chief Scientific Officer and Prof. Dr. Oliver Peters as Chief Medical Officer.
Priavoid GmbH is pleased to announce the appointment of two renowned experts to its executive leadership team. As of June 1, 2025, company co-founder Prof. Dr. Dieter Willbold has taken on the role of Chief Scientific Officer (CSO). Additionally, as of July 1, 2025, Prof. Dr. Oliver Peters joined the team as Chief Medical Officer (CMO).
Prof. Willbold is the scientific mind behind Priavoid’s novel approach to detangle neurotoxic protein aggregates and brings decades of experience in biophysics, structural biology, peptide chemistry and neurobiology, to the CSO role. Prof. Peters, a worldwide renowned clinician in Alzheimer’s disease and psychiatrist with decades of experience earned at the Charité Berlin, amongst others, and who has been closely involved in the ongoing Phase II clinical trial of PRI-002, named PRImus-AD, has already played a central role in shaping its design.
With significant milestones ahead, the expansion of the executive team reflects Priavoid’s commitment to advancing its pipeline with world-class scientific and clinical leadership.
“Our science is entering a decisive phase. I’m proud to continue driving it forward from within the executive team,” said Prof. Dr. Dieter Willbold, Chief Scientific Officer and co-founder of Priavoid.
“Joining Priavoid at this stage feels like a natural next step. I’m excited to contribute to the clinical success of PRImus-AD from a medical position,” added Prof. Dr. Oliver Peters, Chief Medical Officer.
“With Dieter and Oliver, we are strengthening the foundation for Priavoid’s next chapter. Their expertise ensures scientific excellence and clinical rigor at the highest level,” said Prof. em. Dr. Dr. h.c. Detlev Riesner, Chairman of the Supervisory Board.
Patient recruitment for the Phase II PRImus-AD study evaluating PRI-002 in patients with early Alzheimer’s disease was successfully completed in February 2025, with top-line results expected in the second half of 2026. The study is being conducted together with PRInnovation GmbH and is funded by the Federal Agency for Breakthrough Innovation SPRIND.
About Priavoid GmbH:
Priavoid GmbH is a clinical-stage drug developer. The company develops novel all-D-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. All drug candidates are designed with an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. Priavoid is a spin-off of Heinrich Heine University Düsseldorf and Research Center Jülich and was founded in 2017. The company is privately financed, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner.
Downloads
About Priavoid GmbH:
Priavoid GmbH is a clinical-stage drug developer. The company develops novel all-D-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS (amyotrophic lateral sclerosis) or tauopathies. All drug candidates are designed with an anti-prionic mechanism of action to dissolve neurotoxic protein aggregates. Priavoid is a spin-off of Heinrich Heine University Düsseldorf and Research Center Jülich and was founded in 2017. The company is privately financed, including by Qiagen co-founder Prof. em. Dr. Dr. h.c. Detlev Riesner.
